King & Wood Mallesons (KWM) advised the sole sponsor and the underwriters on the HK$177 million global offering and initial public offering of Modern Chinese Medicine Group Co., Ltd. (Modern Chinese Medicine, SEHK Stock Code: 1643) on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK).
Modern Chinese Medicine was listed on the SEHK on 15 January 2021. The listing was priced at HK$1.18 per share and comprised a total of 150,000,000 shares.
Modern Chinese Medicine is principally engaged in the production of proprietary Chinese medicine and offers both over the counter and prescribed medicines intended for the use by the middle-aged and the elderly in the PRC.
The team was led by partner Anthony Wan, with support from senior associate Albert Wong, associates Jason Choi and Annie Chau.
